How do you choose between dupilumab and mepolizumab for managing COPD in patients with eosinophilia?
Community PollStarted
What is your preferred first line agent for managing COPD in patients with eosinophilia?
66 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Pulmonology · Ohio State University Wexner Medical Center
Answered on
I do use both agents and do not have a strong preference. I consider the patient's preference for every 4-week dosing (mepolizumab) vs. every 2-week dosing. Also, if the eosinophil count is between 150 and 300, mepolizumab may be the only option from the insurance perspective.
Join for free or sign in to see the full answer